Source: Annual Congress 2007 - Effect of long acting beta-agonists on severe asthma exacerbations and asthma-related deaths
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Cazzola (Rome, Italy). Inhaled beta2-agonists and death for asthma: can we overcome this risk?. Annual Congress 2007 - Effect of long acting beta-agonists on severe asthma exacerbations and asthma-related deaths

Member's Comments

No comment yet.

Related content which might interest you: Inhaled beta2-agonists in asthma management: an evolving story Source: Breathe 2016; 12: 375-377 Year: 2016 Long-acting beta2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD Source: Eur Respir J 2010; 36: 494-502 Year: 2010 Is there a problem with inhaled corticosteroid use in COPD? Source: Virtual Congress 2020 – Airway diseases Year: 2020 Inhaled corticosteroids and COVID-19 outcomes in asthma: the Israeli experience Source: ERJ Open Res, 8 (1) 00014-2022; 10.1183/23120541.00014-2022 Year: 2022 Inhaled therapies: can they breathe new life into asthma? Source: International Congress 2019 – The journey towards personalized medicine in asthma: where are we now? Year: 2019 Inhaled corticosteroids preventing pneumonia mortality: paradox or selection bias? Source: Eur Respir J, 53 (2) 1802112; 10.1183/13993003.02112-2018 Year: 2019 Inhaled corticosteroids in COPD: the case against Source: Eur Respir J 2009; 34: 13-16 Year: 2009 Inhaled corticosteroids in COPD: a case in favour Source: Eur Respir J 2009; 34: 10-12 Year: 2009 Quintupling inhaled glucocorticoids to prevent childhood asthma exacerbations Source: International Congress 2018 – Preventing asthma and COPD exacerbations by increasing the inhaled glucocorticoid dose Year: 2018 The impact of preventive treatment with long-acting β2 adrenergics agonists and inhaled glucocorticoids in the morbility and mortality of 1.543 events of severe acute exacerbations of asthma Source: Annual Congress 2009 - Epidemiology of atopy and asthma Year: 2009 Does inhaled corticosteroid use affect the risk of ?COVID-19-related death? Source: Breathe, 17 (1) 200275; 10.1183/20734735.0275-2020 Year: 2021 Overuse of short-acting beta-agonists (SABA) and risk factors among patients with asthma Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015 Long-acting bronchodilators in COPD: where are we now and where are we going? Source: Breathe 2014; 10:110-120 Year: 2014 Excess morbidity and mortality in patients with asthma on long-acting beta2-agonists Source: Annual Congress 2007 - Effect of long acting beta-agonists on severe asthma exacerbations and asthma-related deaths Year: 2007 Bronchodilator therapies for severe asthma Source: Eur Respir Mon 2011; 51: 253-267 Year: 2011 Inhaled corticosteroids in the treatment of acute asthma Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002 Inhaled corticosteroids in preschool asthmatics: are they effective and who benefits most? Source: Eur Respir J 2003; 22: Suppl. 45, 534s Year: 2003 What to use INSTEAD of inhaled corticosteroids in COPD? Source: Eur Respir J 2014; 44: 1391-1393 Year: 2014 Combination therapy of inhaled corticosteroids and long-acting beta2-agonists may be associated with risk reduction of lung cancer in COPD patients who quit smoking Source: Eur Respir J 2006; 28: Suppl. 50, 454s Year: 2006